<DOC>
	<DOCNO>NCT02801435</DOCNO>
	<brief_summary>This phase I study evaluate safety , tolerability pharmacokinetics Icotinib Hydrochloride Cream patient mild moderate psoriasis .</brief_summary>
	<brief_title>Icotinib Hydrochloride Cream Patients With Mild Moderate Psoriasis</brief_title>
	<detailed_description>Icotinib Hydrochloride small-molecule epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor , approve treatment advance nonsmall- cell lung cancer ( NSCLC ) China oral form . As EGFR implicate pathogenesis psoriasis , icotinib hydrochloride develop cream treatment mild moderate psoriasis . This single-center , randomize , doubleblind , placebo-controlled study 0.5 % , 1.0 % , 2.0 % , 4.0 % icotinib hydrochloride cream topical administration . Icotinib hydrochloride cream apply subject mild moderate psoriasis . Approximately 40 subject enrol .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Clinical diagnosis plaque psoriasis least six month multiple treatable area ( i.e . lesion face , scalp , genitals skinfolds ) plaque psoriasis cover less 10 % total Body Surface Area ( BSA ) , affected area limb and/or trunk≥ 1 % BSA . A Target Plaque Area ( TPA ) ≥9 cm2 , Target Plaque Severity Score ( TPSS ) ≥ 5 , induration subscore≥2 . Male participant ≥ 50 kg , female participant ≥ 45 kg ; BMI 19 28 kg/m2 ( inclusive ) In good health , history disease major organ abnormality find physical examination vital sign Nonallergic , know history drug allergy Men woman childbearing potential must agree use contraceptive regimen agree doctor trial . Female subject hormonal contraceptive must continue use hormonal contraceptive use past 3 month , route administration dose study Have sign write informed consent enter study Psoriasis guttata , psoriasis punctata , erythrodermic psoriasis , pustular psoriasis , psoriasis arthritis Any dermatological disease might interfere psoriasis clinical evaluation bring subject danger , serious dermatological disease psoriasis . Have receive underlying treatment enter trial : Topical antipsoriasis treatment 2 week , e.g . corticosteroid , retinoids acid , anthranol , tar , keratolytics . Vitamin D analogues local immune regulator treatment 4 week ; Emollient cosmetic 24 hour ; Any psoriasis vaccine , participate psoriasis vaccine trial ; Biologics treatment 12 week , e.g . Alefacept , Etanercept , Infliximab , Adalimumab , Ustekinumab , Efalizumab ; Any phototherapy systemic treatment 4 week , e.g . corticosteroid , methotrexate , retinoids acid , ciclosporin ; Long time exposure natural light artificial UV , exposure ; Use drug know harm certain organ 12 week ; Participated clinical trial 4 week , plan participate trial treatment period ; Any clinically significant central nervous , cardiac , hepatic , renal , gastrointestinal , respiratory , metabolic musculoskeletal system disease history , pathological/physiological condition might disrupt trial result Alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin &gt; 1.5 Upper Limit Normal ( ULN ) , creatinine &gt; ULN History postural hypotension , allergic disease ( asthma , urticaria , atopic dermatitis rhinitis ) Pulmonary disease demonstrate chest Xray examination Physically mentally disable Positive Hepatitis B Surface Antigen ( HBsAg ) , hepatitis C antiHIV test Know allergic active ingredient excipient investigational product Excessive smoker ( &gt; 10 cigarette per day ) , excessive alcohol intake ( &gt; 15g absolute alcohol per day , equal 450ml beer , 150ml wine 50ml lowalcohol Chinese liquor ) Excessive drinking tea , coffee caffeincontaining beverage ( &gt; 8 glass per day ) Drug abuser Poor compliance Under gestation lactation period Other subject investigator 's opinion unsuitable enrol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>EGFR inhibitor</keyword>
	<keyword>topical agent</keyword>
	<keyword>psoriasis</keyword>
	<keyword>phase 1</keyword>
</DOC>